Table 1 Demographic and baseline characteristics (Safety Population)
TP300 | |
|---|---|
N = 19 | |
Sex | |
Male | 13 (68 %) |
Female | 6 (32 %) |
Race | |
Caucasian | 19 (100 %) |
Age in years | |
Mean | 66.1 |
SD | 9.26 |
Median | 67.0 |
Min-Max | 40–82 |
Age (years) | |
< 65 | 7 (37 %) |
> =65 | 12 (63 %) |
Duration from First Diag. to Dose in Days | |
Median | 53.0 |
Min-Max | 33–3648 |
Diagnosis | |
Gastric Adenocarcinoma | 13 (68 %) |
Gastro-oesophageal Junction Adenocarcinoma: Type II | 4 (21 %) |
Gastro-oesophageal Junction Adenocarcinoma: Type II | 2 (11 %) |
ECOG Performance Status | |
0 | 12 (63 %) |
1 | 7 (37 %) |
Prior Surgery | |
No | 13 (68 %) |
Yes | 6 (32 %) |
Prior Radiotherapy | |
No | 19 (100 %) |
Prior Neoadjuvant Chemotherapy | |
No | 17 (89 %) |
Yes | 2 (11 %) |
Prior Adjuvant Chemotherapy | |
No | 16 (84 %) |
Yes | 3 (16 %) |